The composition 1 tablets:
- active substance: inosine pranobex;
- 1 tablet contains inosine pranobex 500 mg;
- excipients: wheat starch, povidone, mannitol (E 421), magnesium stearate.
Dosage form. Tablets.
Main physical and chemical properties: oval tablets with biconvex surface from almost white to cream color.
10 tablets in a blister. 2 or 4 blisters in a box.
Indication for use:
Viral infections caused by herpes simplex virus types 1 and 2, chickenpox virus, cytomegalovirus, Epstein-Barr virus, measles virus, mumps virus, including in patients with immunodeficiency;
- viral respiratory infections;
- papillomavirus infections of the skin and mucous membranes: genital warts, papillomavirus infection of the vulva, vagina and cervix (as part of complex therapy);
- acute viral encephalitis (as part of complex therapy);
- viral hepatitis (as part of complex therapy);
- subacute sclerosing panencephalitis (as part of complex therapy).
Hypersensitivity to the active substance or to any other component of the drug; acute gout attack; hyperuricemia.
Method of application.
The drug is administered orally.
The daily dose depends on body weight, course and severity of the disease, the patient’s condition. Adults and children from 12 years: 50 mg/kg body weight (usually 6-8 tablets, divided into 3-4 doses), the maximum daily dose is 4 g. Children from 1 to 12 years: 50 mg/kg body weight (usually 1 tablet per 10 kg of body weight for a child with a bodyweight of 10-20 kg, with a bodyweight of more than 20 kg prescribe a dose, as for adults) for 3-4 doses per day, the maximum daily dose is 4 g. To facilitate swallowing, the tablet can be to crushed.
Duration of treatment.
Acute diseases: in diseases with a short course, the course of treatment is from 5 to 14 days. After reducing the severity of symptoms, treatment should be continued for another 1-2 days or longer, depending on the course of the disease, the patient’s condition. Long-term viral diseases: treatment should be continued for 1-2 weeks after the reduction of the symptoms of the disease or longer, depending on the course of the disease, the patient’s condition.
Recurrent diseases: in the initial stage of treatment, the same recommendations are used for acute diseases. During maintenance therapy, the dose can be reduced to 500-1000 mg (1-2 tablets) per day. At the first signs of recurrence, it is necessary to restore the daily dose recommended for acute diseases, and treatment should be continued for 1-2 days after the disappearance of symptoms. The course of treatment can be repeated several times, depending on the patient’s condition, on the advice of a doctor. Chronic diseases: the drug is prescribed in a daily dose of 50 mg/kg body weight in accordance with the following schemes:
asymptomatic diseases – take for 30 days with a break of 60 days;
diseases with moderate symptoms – take for 60 days with a break of 30 days;
diseases with severe symptoms – apply for 90 days with a break of 30 days.
The course of treatment should be repeated as many times as necessary, and it is necessary to constantly monitor the patient’s condition and indications for continued therapy. For infections caused by the human papillomavirus (external genital warts (genital warts) or cervical papillomavirus infection) take 3 g (2 tablets 3 times a day) for 14-28 days as monotherapy or as an adjunct to topical therapy or surgical treatment according to the following schemes:
for the treatment of patients from the “low risk” group (patients with normal immunity or patients with a low risk of recurrence) the drug is used for 14-28 days until the maximum eradication of the virus, then a break of 2 months should be taken. The course of treatment can be repeated with the use of the same dose, it is necessary to monitor the patient’s condition and indications for continued therapy;
for the treatment of patients from the group of “high risk” * (patients with immunodeficiency or high risk of recurrence) the drug is used 5 days a week, 1-2 weeks a month for 3 months. The course of treatment should be repeated as many times as necessary, and it is necessary to constantly monitor the patient’s condition.
and indications for continued therapy.
* Factors of “high risk” in patients with recurrence or dysplasia of the cervix, or papillomavirus infection of the genitals, as in other similar diseases, include:
– Immunodeficiency caused by:
presence in the anamnesis of chronic or recurrent infections or diseases which are sexually transmitted;
– long-term use of oral contraceptives (2 years and longer);
– the level of folate in erythrocytes is less than 660 nmol / l;
– the presence of several sexual partners, a change of permanent sexual partner;
– frequent vaginal intercourse (≥ 2-6 times a week) or anal sex;
– atopy (hereditary predisposition to hypersensitivity);
– poorly controlled diabetes;
– papillomavirus infection of the genitals, which lasts more than 2 years or has 3 or more recurrences in the anamnesis;
– a history of skin warts in childhood.
In subacute sclerosing panencephalitis, the daily dose is 100 mg/kg body weight, the maximum dose is 3-4 g per day, and it is necessary to monitor the patient’s condition and indications for continued therapy.
The drug is used for children from 1 year.